NCT06480604Recruiting
Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis
A Pilot Clinical Trial Assessing the Effect of a Multi-strain Probiotic on the Risk of Recurrence and Severity of Symptoms in Females With Recurrent Vulvovaginal Candidiasis
Source: ClinicalTrials.gov · Last updated 7 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study evaluates the effect of a multi-strain probiotic on the risk of recurrence and severity of symptoms in females with recurrent vulvovaginal candidiasis (R-VVC).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 126 (estimated)
- First submitted
- 25 Jun 2024
- Start date
- 15 Oct 2024
- Primary completion date
- Jul 2025
- Lead sponsor
- The Archer-Daniels-Midland Company
- NCT number
- NCT06480604
What you commit to
- Study type: Interventional
- Planned participants: 126
- From 15 Oct 2024 to the primary completion date, Jul 2025
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of oral or vaginal anti-fungal medication in the last 14 days.
- Women not willing to use any form of vaginal medication during the study.
- Use of corticosteroids therapy in the last 30 days.
- Use of oral/systemic antimicrobial therapy in the last 30 days.
Other illness
- Known allergy to Clotrimazole.
- Diagnosed with compromised immune system, type I and/or type II diabetes mellitus, or malignancies.
- Known allergy to the study products or azoles.
- Individuals with a history of frequent infections requiring antibiotic treatments.
- Women with uncontrolled hypertension with systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg.
- History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders that, in the judgment of the Investigator, would interfere with the participant's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the individual at undue risk.
- Presence of unstable, acutely symptomatic, or life-limiting illness.
Other
- Individuals meeting ANY of the following criteria will be excluded from the study:
- Post-menopausal and peri-menopausal women.
- Pregnant/breast-feeding women.
- Vaginal culture suggestive of bacterial vaginosis (Nugent's score of 7-10), trichomonas vaginalis or Gardnerella vaginalis.
- Participants found positive for Clotrimazole resistance, by vaginal culture \& sensitivity at screening.
- Use of vaginal douching.
- Unwillingness to use an appropriate method of contraception.
- Participation in another clinical study(ies) in the last 3 months.
- Women who, in the opinion of the Investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the study.
- Heavy alcohol drinkers defined as follows: For men, consuming more than 4 drinks on any day or more than 14 drinks/week. For women, consuming more than 3 drinks on any day or more than 7 drinks/week.
- Smokers.
- Use of any supplements (includes probiotics, post-biotics, herbal supplements, synbiotics, enzyme supplements, vitamins with probiotics) in the last 30 days.
Who the study is looking for
- Individuals meeting ALL of the following criteria will be enrolled for the study:
- Premenopausal women aged 18-50 years.
- Women with a culture-confirmed active episode caused by Candida spp. (albicans or non-albicans) reported within 24-48 hours of evidence of clinical symptoms. (No medications should have been initiated before the sample for culture is collected).
- Documented history of recurrence of at least 3 VVC episodes in the last 12 months confirmed by vaginal culture /clinical diagnosis.
- Culture growth of Candida spp. causing VVC.
- Random Capillary Blood Glucose of \< 110mg/dl.
- Willingness to consume the study products for the entire study duration.
- Willing to complete all study procedures and comply with study requirements.
- Willing to abstain from other supplements or medication.
- Ready to give voluntary, written, informed consent to participate in the study.
Age in the registry: 18 years to 50 years · Sex: Female · Accepts healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Life care Hospital Coordinator of this site? Confirm its status | Nashik | India | Recruiting |
| ENT & Vertigo Clinic Coordinator of this site? Confirm its status | Pune | India | Recruiting |
| AMF's Moraya Multispeciality Hospital Coordinator of this site? Confirm its status | Pune | India | Recruiting |
| Vivaan Hospital Coordinator of this site? Confirm its status | Sopāra | India | Recruiting |
| Anand Multispeciality Hospital Coordinator of this site? Confirm its status | Vadodara | India | Recruiting |
| Matritva Women's Hospital Coordinator of this site? Confirm its status | Vasai | India | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.